PLEASANTON, Calif., Jan. 3, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the 31st Annual J.P. Morgan Healthcare Conference on Monday, January 7.
Gary F. Burbach, President and Chief Executive Officer, will provide an update on the company, beginning at 8:00 a.m., Pacific Standard Time (11:00 a.m., Eastern Standard Time).
The presentation and ensuing breakout session will be available through the conference website at http://jpmorgan.metameetings.com/webcasts/healthcare13/directlink?ticker=THOR, or on the company's website at http://www.thoratec.com.
Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's products include the HeartMate® LVAS (Left Ventricular Assist System) and Thoratec® VAD (Ventricular Assist Device) with more than 20,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures and distributes the CentriMag® and PediMag®/PediVAS® product lines. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's website at http://www.thoratec.com.
Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered trademarks of Thoratec Corporation and IVAD is a trademark of Thoratec Corporation. CentriMag and PediMag are registered trademarks of Thoratec LLC, and PediVAS is a registered trademark of Thoratec Switzerland GmbH.
SOURCE Thoratec Corporation